All In Biotech

Drug Trial Radar · NCT07777211

A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Mar 31, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I/IIa, multicenter study designed to evaluate the safety, tolerability, and efficacy of GKL-006 injection in patients with ductal adenocarcinoma of pancreas.

Conditions

  • Advanced Pancreatic Cancer
  • Ductal Adenocarcinoma of Pancreas

Interventions

  • GKL-006 injectionBiological

    GKL-006 injection will be administered at the protocol-defined dose every 2 weeks. Participants in Phase I will receive the assigned low or high dose, and recommended dose in Phase II.

  • Nab-paclitaxel and GemcitabineDrug

    Nab-paclitaxel and Gemcitabine are given intravenously as a combination chemotherapy regimen according to the study protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Incidence of Dose-Limiting ToxicitiesTime frame: From the first dose until 42 days
  2. Phase I: Incidence and Severity of Adverse Events and Serious Adverse EventsTime frame: Up to 18 months
  3. Phase II: Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC) per RECIST 1.1Time frame: Up to 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • No. 1 Shuaifuyuan, Wangfujing, Dongcheng District

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.